Molecular mechanisms in signal transduction: New targets for the therapy of gynecologic malignancies

被引:5
作者
Gabriel, B
Fischer, DC
Kieback, DG
机构
[1] Univ Klin Maastricht, Abt Frauenheilkunde & Geburtshilfe, NL-6202 AZ Maastricht, Netherlands
[2] Univ Freiburg, Frauenklin, D-7800 Freiburg, Germany
来源
ONKOLOGIE | 2002年 / 25卷 / 03期
关键词
signal transduction; breast cancer; ovarian cancer; HER2; EGFR;
D O I
10.1159/000064317
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Growth factor-mediated signal transduction pathways in gynecologic malignancies are summarized. Targeting critical tyrosine kinase pathways may lead to more specific anticancer regimens in gynecologic oncology. During the past 10 years significant progress in cancer treatment has been made through the discovery of potent specific and well-tolerated inhibitors of signal transduction. Improved understanding of molecules involved in signal transduction pathways will undoubtedly result in an increasing number of compounds under clinical investigation. Some of the described molecular therapeutic approaches are suitable to enrich the conventional chemotherapy.
引用
收藏
页码:240 / 247
页数:10
相关论文
共 70 条
[1]   Increased dosage and amplification of the focal adhesion kinase gene in human cancer cells [J].
Agochiya, M ;
Brunton, VG ;
Owens, DW ;
Parkinson, EK ;
Paraskeva, C ;
Keith, WN ;
Frame, MC .
ONCOGENE, 1999, 18 (41) :5646-5653
[2]  
Baekelandt M, 1999, ANTICANCER RES, V19, P4469
[3]   OVEREXPRESSION OF THE C-ERBB-2 ONCOPROTEIN - WHY DOES THIS OCCUR MORE FREQUENTLY IN DUCTAL CARCINOMA INSITU THAN IN INVASIVE MAMMARY-CARCINOMA AND IS THIS OF PROGNOSTIC-SIGNIFICANCE [J].
BARNES, DM ;
BARTKOVA, J ;
CAMPLEJOHN, RS ;
GULLICK, WJ ;
SMITH, PJ ;
MILLIS, RR .
EUROPEAN JOURNAL OF CANCER, 1992, 28A (2-3) :644-648
[4]   ZD1839 ('Iressa')1,2 as an anticancer agent [J].
Baselga, J ;
Averbuch, SD .
DRUGS, 2000, 60 (Suppl 1) :33-40
[5]  
Bauer M., 1997, General and Diagnostic Pathology, V143, P185
[6]  
BERCHUCK A, 1990, CANCER RES, V50, P4087
[7]   HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer [J].
Berry, DA ;
Muss, HB ;
Thor, AD ;
Dressler, L ;
Liu, ET ;
Broadwater, G ;
Budman, DR ;
Henderson, IC ;
Barcos, M ;
Hayes, D ;
Norton, L .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (20) :3471-3479
[8]   Functional analysis of Csk and CHK kinases in breast cancer cells [J].
Bougeret, C ;
Jiang, SX ;
Keydar, I ;
Avraham, H .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (36) :33711-33720
[9]   c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases [J].
Carlomagno, C ;
Perrone, F ;
Gallo, C ;
DeLaurentiis, M ;
Lauria, R ;
Morabito, A ;
Pettinato, G ;
Panico, L ;
DAntonio, A ;
Bianco, AR ;
DePlacido, S .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (10) :2702-2708
[10]  
Chan KC, 2002, CANCER RES, V62, P122